Polycystic Kidney Disease Drugs Market Trends

Growth Drivers

• The Surge in the Incidence of Autosomal Dominant Polycystic Kidney Diseases (ADPKD) - ADPKD is a rare condition, as it contributes significantly to chronic kidney disease and kidney failure. In addition, polycystic kidney disease, the most common chronic kidney disease, substantially increases the prevalence of chronic kidney disease. As a result, an increasing prevalence of ADPKD is expected to drive global polycystic kidney disease drugs market growth over the forecast period. For instance, around 200,000 to 500,000 people in the United States and another 13,000,000 people around the world suffer from ADPKD, and only about 25% of the population is aware of the disease.

• Growing Initiatives to Raise Awareness About PKDs - For instance, PKD Foundation is the only non-profit in the U.S. exclusively dedicated to treating and curing polycystic kidney disease. Over 1,300 research studies were funded and USD 1.5 billion in research funding has been leveraged.

• Increasing Healthcare Spending Worldwide - According to the Centers for Medicare & Medicaid Services, the United States spent USD 4.1 trillion on healthcare services in 2020, representing 19.7% of the GDP.

• Rising Number of Research and Development Activities - According to the World Bank, the number of researchers in R&D activities has increased from 14,12 researchers per million in 2015 to 1,597 researchers per million in 2018.

• Growth in Personal Disposable Income - According to the Bureau of Economic Analysis, in the United States, personal income increased by USD 47.0 billion (0.2%) in July 2020, and disposable personal income expanded by USD 37.6 billion (0.2%).

Challenges

• Insufficient Number of Approved Drugs - There are a few drugs available to treat polycystic kidney disease, and researchers are still working to discover more medicines and drugs for the effective treatment of the disease. Hence, this factor is considered to be one of the major restraints for the market in the coming years.

• Strict Government Guidelines for Drug Trials

• High Expenses Associated with Treatment